// App-Quantinova.ai

OA0166 : Improvement in disease‐specific quality of life for peanut‐allergic subjects receiving AR101 maintenance therapy

Researchers

Presenter

  • Hourihane JO

Principal Investigators

  • Johnston D

  • Lieberman JA

  • Birchwood C

  • Acaster S

  • Marciniak A

  • Vereda A

  • Zawadzki R

  • Hass S

  • DunnGalvin A

  • Dubois A

  • Wang J

Medical Centers

  • University College Cork, Cork, Ireland

  • Asthma & Allergy Specialists, Charlotte, United States

  • Division of Allergy and Immunology, The University of Tennessee Health Science Center, Le Bonheur Children's Hospital, Memphis, United States

  • Aimmune Therapeutics, Brisbane, United States

  • Acaster Lloyd Consulting, London, , United Kingdom

  • ADC Therapeutics, London, United Kingdom

  • H. E. Outcomes, LLC, Los Angeles, United States

  • University of Groningen, Groningen, Netherlands

  • Icahn School of Medicine at Mount Sinai, Jamaica, NY, United States

Locations

  • Ireland

  • United States

  • United Kingdom

  • Netherlands

Companies

  • N/A

Study Components

Therapeutic Area

  • N/A

Disease

  • N/A

Biomarkers

  • N/A

Drug/Treatment

  • N/A

Outcome

  • N/A

Study Design

  • N/A

Phase

  • III

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved